# Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014

Source: https://onco.cc/key-papers/paper-scott-tnbc-disparities-uscs-cancer-2019/  
OnCo record `paper-scott-tnbc-disparities-uscs-cancer-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A count of 1.15 million US breast cancers from 2010 to 2014 in which Black women had 2.27 times the odds of a triple-negative diagnosis and women under 40 nearly twice the odds, confirming the disparity at national scale.

## Summary

Scott, Mobley, Kuo and Il'yasova examined differences between triple-negative and other breast cancers by age, race and ethnicity and stage in the United States Cancer Statistics database. Of 1,151,724 breast cancers identified from 2010 through 2014, the triple-negative phenotype accounted for about 8.4 percent. In unadjusted analyses non-Hispanic Black women (odds ratio 2.27, 95 percent confidence interval 2.23 to 2.31) and Hispanic women (1.22, 1.19 to 1.25) had higher odds of a triple-negative diagnosis than non-Hispanic white women; women under 40 had the highest odds compared with women aged 50 to 64 (1.95, 1.90 to 2.01); stage III (1.69) and stage IV (1.47) at diagnosis conferred higher odds. Results varied slightly after adjustment.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: tnbc-evidence
- Journal: Cancer
- Year: 2019
- DOI: 10.1002/cncr.32207
- Authors: Scott LC, Mobley LR, Kuo TM, et al.
- Findings: Triple-negative phenotype in about 8.4 percent of 1,151,724 US breast cancers, 2010 to 2014.; Odds of triple-negative diagnosis: non-Hispanic Black 2.27 (95 percent CI 2.23 to 2.31); Hispanic 1.22; age under 40 1.95; stage III 1.69; stage IV 1.47.
- What it means: The most recent national figure behind the statement that Black women in the United States have about twice the incidence of triple-negative breast cancer; trial enrolment has not matched it.
- Caveats: Unadjusted odds ratios are the headline figures; adjusted results differed slightly.; The 8.4 percent share is lower than SEER's 12.2 percent, reflecting unknown-status coding across registries.

## Sources

- Cancer 2019: https://doi.org/10.1002/cncr.32207
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31282032/

## Connected records

- key papers: [Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry](https://onco.cc/key-papers/paper-bauer-triple-negative-california-registry-cancer-2007/), [US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status](https://onco.cc/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/)
- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- ideas: [Close the gap between who gets triple-negative breast cancer and who is in its trials](https://onco.cc/ideas/idea-tnbc-disparities-in-access-and-outcomes/), [Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics](https://onco.cc/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/)

---
JSON: https://onco.cc/api/v1/entities/paper-scott-tnbc-disparities-uscs-cancer-2019.json